Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study
Open Access
- 28 February 2015
- journal article
- research article
- Published by Elsevier BV in EBioMedicine
- Vol. 2 (4), 317-323
- https://doi.org/10.1016/j.ebiom.2015.02.007
Abstract
No abstract availableKeywords
Funding Information
- Medical & Biological Laboratories Co., Ltd
This publication has 29 references indexed in Scilit:
- Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kitBMC Cancer, 2013
- KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancerBritish Journal of Cancer, 2012
- A Comprehensive Survey of Ras Mutations in CancerCancer Research, 2012
- KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximabBritish Journal of Cancer, 2011
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicineBritish Journal of Cancer, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR–SSOP–Luminex method in the Japanese populationImmunogenetics, 2005